Discovery of 2,3,5-trisubstituted pyridine derivatives as potent Akt1 and Akt2 dual inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 15, Issue 4, 2005, Pages 905-909

  Zhao, Zhijian ^a   Leister, William H ^a   Robinson, Ronald G ^a   Barnett, Stanley F ^a   Defeo Jones, Deborah ^a   Jones, Raymond E ^a   Hartman, George D ^a   Huff, Joel R ^a   Huber, Hans E ^a   Duggan, Mark E ^a   Lindsley, Craig W ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Akt; Inhibitor; Kinase; Pyridine; Tetrazole

Indexed keywords

PROTEIN KINASE B; PROTEIN KINASE B BETA; PROTEIN KINASE INHIBITOR; PYRIDINE DERIVATIVE;

AMINATION; ARTICLE; DRUG POTENCY; ENZYME INHIBITION; IC 50; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION; SUZUKI REACTION;

EID: 20144388779     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2004.12.062     Document Type: Article

References (20)

1. For excellent reviews on Akt see: J.R. Graff Expert Opin. Ther. Targets 6 2002 103
2. K.M. Nicholson, and N.G. Anderson Cell. Signal. 14 2002 381
3. Q. Li, and G.-D.. Zhu Curr. Top. Med. Chem. 2 2002 939
4. S. Hanks, and T. Hunter FASEB 9 1995 576
5. M.J. Zinda, M.A. Johnson, J.D. Paul, C. Horn, B.W. Konicek, Z.H. Lu, G. Sandusky, J.E. Thomas, B.L. Neubauer, M.T. Lai, and J.R. Graff Clin. Cancer Res. 7 2001 2475
6. J.Q. Cheng, B. Ruggeri, W.M. Klein, G. Sonoda, D.A. Altomare, D.K. Watson, and J.R. Testa Proc. Natl. Acad. Sci. U.S.A. 93 1996 3636
7. D. Haas-Kogan, N. Shalev, M. Wong, G. Mills, G. Yount, and D. Stokoe Curr. Biol. 8 1998 1195
8. S.P. Staal Proc. Natl. Acad. Sci. U.S.A. 84 1987 5034
9. J. Brognard, A.S. Clark, Y. Ni, and P.A. Dennis Cancer Res. 61 2001 3986
10. A.P. Kozikowski, H. Sun, J. Brognard, and P.A. Dennis J. Am. Chem. Soc. 125 2003 1144
11. C.B. Breitenlechner, T. Wegge, L. Berillon, K. Graul, K. Marzenell, W. Friebe, U. Thomas, R. Huber, R.A. Engh, and B. Masjost J. Med. Chem. 47 2004 1375
12. J.H. Hsu, Y. Shi, L.P. Hu, M. Fisher, T.F. Franke, and A. Lichtenstein Oncogene 21 2002 1391
13. C. Page, H. Lin, Y. Jin, V.P. Castle, G. Nunez, M. Huang, and J. Lin Anticancer Res. 20 2000 407
14. C.W. Lindsley, Z. Zhao, W.H. Leister, R.G. Robinson, S.F. Barnett, D. Defeo-Jones, R.E. Jones, G.D. Hartman, J.R. Huff, H.E. Huber, and M.E. Duggan Bioorg. Med. Chem. Lett. 15 2005 761
15. For Akt enzyme assay details and the proposed model for the allosteric mode of inhibition of these inhibitors, see: Barnett, S. F.; Defeo-Jones, D.; Fu, S.; Hancock, P. J.; Haskell, K. M.; Jones, R. E.; Kahana, J. A.; Kral, A.; Leander, K.; Lee, L. L.; Malinowski, J.; McAvoy, E. M.; Nahas, D. D.; Robinson, R.; Huber, H. E. Biochemistry, in press
16. C.G. Blettner, W.A. Koenig, W. Stenzel, and T. Schotten J. Org. Chem. 64 1999 3885
17. Compounds 9,13, and 16 were obtained from the Merck internal sample collection
18. S.V. Ley, M.H. Bolli, B. Hinzen, A. Gervois, and B. Hall J. Chem. Soc., Perkin Trans. 1 1998 2239
19. Z.P. Demko, and K.B. Sharpless J. Org. Chem. 66 2001 7945
20. Similar behavior was observed with a carboxylate in the 5-position, which was alleviated when the corresponding methyl ester analog was tested, providing further evidence of zwitterionic character affording poor cell permeability in this series